Lazard Asset Management
TRDA icon

Lazard Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Lazard Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,256
Closed -$8K – 2316
2025
Q2 		$8K Sell
1,256
-38,455
-97% -$309K ﹤0.01% 2182
2025
Q1 		$358K Sell
39,711
-15,806
-28% -$197K ﹤0.01% 1499
2024
Q4 		$959K Buy
55,517
+16,076
+41% +$291K ﹤0.01% 1169
2024
Q3 		$630K Buy
39,441
+36,359
+1,180% +$573K ﹤0.01% 1290
2024
Q2 		$43K Buy
3,082
+2,907
+1,661% +$41.3K ﹤0.01% 1955
2024
Q1 		$2K Sell
175
-2,493
-93% -$35.3K ﹤0.01% 1945
2023
Q4 		$40K Buy
+2,668
New +$39.5K ﹤0.01% 1949
2023
Q3 		– Sell
-2,417
Closed -$36K – 2473
2023
Q2 		$36K Buy
+2,417
New +$33.3K ﹤0.01% 1935

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Lazard Asset Management's TRDA Position: Q3 2025 in Review

Lazard Asset Management sold out of Entrada Therapeutics (TRDA) in Q3 2025, closing a stake of 1,256 shares — an estimated $8K sold.

Lazard Asset Management first reported a position in TRDA in Q2 2023 and held it in 8 quarters. The position peaked at $959K in Q4 2024. 117 funds tracked by Wall St. Rank hold TRDA as of Q3 2025.

  • Lazard Asset Management reported no remaining Entrada Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 1,256 Entrada Therapeutics shares in Q3 2025, an estimated $8K.
  • Lazard Asset Management first reported a position in Entrada Therapeutics in Q2 2023 and held it in 8 quarters.
  • Lazard Asset Management's Entrada Therapeutics position peaked at $959K in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.